https://www.selleckchem.com/pr....oducts/conteltinib-c
A logistic regression model and an analysis of covariance model were used to analyze treatment comparisons of categorical and continuous measures, respectively. Statistically significant (p ≤ 0.05) improvements were observed as early as week1 or 2 for the baricitinib group compared to placebo in almost all main efficacy measures. For other outcomes including 66 swollen joint count, 68 tender joint count, FACIT-F, and DAS28-hsCRP ≤ 3.2 response rate, differences were evident (p ≤ 0.05) by week4 in the baricitinib group compare
Like
Comment
Share
